Navigation Links
D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)
Date:8/17/2009

occurring in stroke patients and emerged from D-Pharm's proprietary Membrane Activated Chelator (MAC) platform technology. Both preclinical and clinical Phase I and II studies indicate a favorable efficacy and safety profile for DP-b99. In the recently completed Phase IIb trial in 150 ischemic stroke patients, DP-b99 increased by two-fold the percentage of patients that completely recovered from ischemic stroke. DP-b99 may be administered within a nine hour therapeutic window.

About Stroke

Every year around 1.5 million people in the U.S., Western Europe and Japan suffer an acute stroke. Stroke is a leading cause of death in the western world and around 50% of stroke survivors suffer from some form of severe disability. According to the American Heart Association (AHA) the annual economic burden of stroke in the U.S. is approaching $70B USD in 2009. Currently, between 2-5% of stroke patients receive tissue plasminogen activator (tPA), the only drug currently approved for treatment of acute stroke in the U.S.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is a clinical stage, biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products, DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. DP-VPA, a prodrug of valproic acid, is in Phase II clinical development. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer.

Disclaimer

This press release shall not constitute an offer to sell
'/>"/>

SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
2. Globus Medical Raises $110 Million in Series E Financing Round
3. EntreMed Raises $20 Million to Support Clinical Development Program
4. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
5. Romark Laboratories Raises $18 Million in Institutional Financing
6. Light Sciences Oncology Raises $40.1 Million in Series C Financing
7. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
8. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
9. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
10. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
11. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or ... a noninvasive  device that tracks blood glucose levels, announced today ... its new scientific advisory board that is expected to ... research, monitoring and treatment. Prof. Dr. ... and Head, Business Development of Profil Institute for Metabolic ...
(Date:2/26/2015)... , Feb. 26, 2015 People ... have the opportunity to participate in research that ... the first independent U.S. psoriasis registry begins recruiting ... joint collaboration with the National Psoriasis Foundation and ... reporting for secukinumab, a new biologic medication by ...
(Date:2/26/2015)... , Feb. 26, 2015 Surna Inc. ... specializing in commercial indoor cannabis cultivation technology, announced ... from start-up to fast-paced manufacturing and engineering company. ... , current Director and CEO, will be stepping ... proud of what the team has accomplished thus ...
Breaking Medicine Technology:Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4First independent U.S. psoriasis registry will track drug safety and effectiveness 2First independent U.S. psoriasis registry will track drug safety and effectiveness 3Surna, Inc. Announces Senior Leadership Changes 2Surna, Inc. Announces Senior Leadership Changes 3Surna, Inc. Announces Senior Leadership Changes 4
... 1, 2011 PTC Therapeutics, Inc. (PTC) today announced ... of ataluren, an investigational new drug, in adults with ... Respiratory Journal . The published three-month data showed that ... chloride channel activity, CF-related cough and positive trends in ...
... READING, England and BEDMINSTER, N.J., June 30, 2011 ... Inc., today announced that the U.S. Food and Drug ... the management of breakthrough pain in cancer patients 18 ... and who are tolerant to opioid therapy for their ...
Cached Medicine Technology:Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 2Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 3Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 4Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 5Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 2FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 3FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 4FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 5FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 7FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 8
(Date:2/26/2015)... New location, same quality of ... it is accepting new patients at its newly ... , The new location opened its doors Feb. ... programs, including the following programs: , Comprehensive physical ... -Vestibular rehabilitation, -Neurological rehabilitation, -Balance and fall prevention, ...
(Date:2/26/2015)... 2015 Miami auto accident lawyer, Sean M. ... a new, useful addition by making it possible for drivers ... , “Given the fact that last year (2014) was a ... keeping drivers - especially those car accident victims who were ... recall issues is important.” – Personal injury lawyer, Sean M. ...
(Date:2/26/2015)... The report segments the European patient handling equipment ... accessory, and region. The medical beds segment accounted ... handling equipment market, by product. However, the nonmechanical ... highest CAGR in the forecast period. , ... On the basis of type of care, the ...
(Date:2/26/2015)... Imagine a day without access to clean, drinkable water and ... no one to help. For more than 783 million people ... than 2.5 billion people will also lack access to basic ... led by Nevada’s Desert Research Institute (DRI) is ... – who often bear the brunt of the impact from ...
(Date:2/26/2015)... Ore. (PRWEB) February 26, 2015 ... services, celebrated its launch to its first customer ... employees and their covered dependents. , SpendWell ... health care services, combining real-time price transparency with ... a variety of routine health care services and ...
Breaking Medicine News(10 mins):Health News:Tidewater Physical Therapy Accepting New Patients at Relocated Battlefield Clinic 2Health News:Auto Recalls Additional Feature, Sean M. Cleary Miami Auto Accident Lawyer 2Health News:European Patient Handling Equipment Market Hit to $5,150.2 Million by 2019 - New Resaerch Report by MarketsanMarkets 2Health News:European Patient Handling Equipment Market Hit to $5,150.2 Million by 2019 - New Resaerch Report by MarketsanMarkets 3Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 3Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 2Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 3
... of Medicine may have found a way to turn an ... normal cells are starved for food, they chew up existing ... that process, called autophagy, using it to survive when they ... from chemotherapy and other sources. When the Penn investigators ...
... more than 100,000 patients in the U.S. undergo implantation ... rhythm abnormalities. This number constitutes a 20-fold increase over ... of end of life care of these medical devices, ... options. Now, researchers at the University of Pennsylvania School ...
... April 5 (HealthDay News) -- The inner ear can actually "store" ... in the inner ear continue even after a sound has ended ... The study is published in the April 5 issue of the ... investigators found that after-vibrations in the inner ear were dependent on ...
... April 5, 2011 Despite a growing number of cities ... up everywhere from chic downtown cafes to locations near ... young adults. A new study done by researchers at ... popular pastime, and the results are discouraging. "The ...
... Cardiac & Vascular Institute at NYU Langone Medical Center ... Cardiology 60th Annual Scientific Session held April 2-5, 2011 ... NYU Langone cardiologists included: The Relationship between ... vs. Aspirin Alone: Results from the CHARISMA Trial , ...
... By Ellin Holohan HealthDay Reporter , MONDAY, April ... long workday to the list of risk factors for heart disease. ... in England significantly increased their chances of having a heart attack ... by researchers at University College London, found that employees who regularly ...
Cached Medicine News:Health News:Modern targeted drug plus old malaria pill serve a 1-2 punch in advanced cancer patients 2Health News:Penn study sheds light on end of life management of implanted defibrillators 2Health News:Hookah use widespread among college students 2Health News:Hookah use widespread among college students 3Health News:NYU Langone Medical Center cardiologists present at ACC 60th Annual Scientific Session 2Health News:NYU Langone Medical Center cardiologists present at ACC 60th Annual Scientific Session 3Health News:NYU Langone Medical Center cardiologists present at ACC 60th Annual Scientific Session 4Health News:Too Many Hours at Work Might Harm the Heart 2Health News:Too Many Hours at Work Might Harm the Heart 3
... Shoulder Holder is used for positioning the ... position. The shoulder holder is adjustable with ... arm positions and sizes. The MITT allows ... arm in the shoulder holder during surgery. ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Made exclusively from LactoSorb® Resorbable Copolymer....
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
Medicine Products: